Clinical trials: sponsored by InventisBio Co., Ltd
NSCLC
Study to Evaluate D-1553 in Subjects With Lung Cancer
This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic…
- Trial name
- NCT05383898
- Testing
- D-1553
- Where
- 2 sites in China
- Volunteers
- 225 people
- Sponsor
- InventisBio Co., Ltd
NSCLC
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Trial name
- NCT05492045
- Testing
- D-1553, Other
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- InventisBio Co., Ltd
Healthy Male
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
This is a phase I study to evaluate drug-drug interactions (DDIs) of D-1553 as a perpetrator combined with midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), rosuvastatin (OATP1B1/OATP1B3 substrate), furosemide…
- Trial name
- NCT06105255
- Testing
- D-1553
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Solid Tumor, NSCLC
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of D-0316 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Conditions
- Solid Tumor, NSCLC, EGFR T790M
- Trial name
- NCT03861156
- Testing
- D-0316
- Where
- China
- Volunteers
- 290 people
- Sponsor
- InventisBio Co., Ltd
Mass Balance Study
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
To quantitatively analyze the total radioactivity (TRA) in excrement after a single oral dose of [14C] D-1553 in healthy subjects, and obtain radioactivity recovery and primary excretion pathways in humans; To obtain radioactive…
- Trial name
- NCT06233916
- Testing
- [14C] D-1553
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Breast Cancer
A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate…
- Trial name
- NCT03471663
- Testing
- D-0502, palbociclib
- Where
- 15 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- InventisBio Co., Ltd
Advanced Non Small Cell Lung Cancer
D-0316 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of D-0316 administered orally in patients with advanced NSCLC who have progressed following prior therapy with an EGFR-TKI (Epidermal Growth Factor Receptor tyrosine kinase inhibitor…
- Trial name
- NCT03452150
- Testing
- D-0316
- Where
- 3 sites in China
- Volunteers
- 84 people
- Sponsor
- InventisBio Co., Ltd
Mass Balance Recovery
Study in Healthy Adult Female Subjects
An Open Label Phase 1 Study in Healthy Adult Female Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C] D-0502 Following Single Oral Dose Administration
- Trial name
- NCT05339633
- Testing
- [14C]-D-0502
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Healthy
Evaluation of PK and Safety of D-0120 and Allopurinol
Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects
- Trial name
- NCT05360628
- Testing
- D-0120 in combination with Allopurinol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Healthy Female Volunteer
Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects
Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects
- Trial name
- NCT05226338
- Testing
- D-0502
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Hyperuricemia or Gout
D-0120 Safety and PK/PD Study in China
It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose, dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy subjects and…
- Trial name
- NCT03923868
- Testing
- D-0120
- Where
- 6 sites in China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Healthy Volunteers
Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers
This phase 1 study is a randomized, double-blind, placebo controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy volunteers.
- Trial name
- NCT04097405
- Testing
- D-0120
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Breast Cancer
Food Effect Study of D-0502 Tablet in Healthy Volunteers
This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.
- Trial name
- NCT03810625
- Testing
- D-0502
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Gout
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting…
- Trial name
- NCT03291782
- Testing
- D-0120
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd